These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 8388487)
21. Purification of a mouse nuclear factor that binds to both the A and B cores of the polyomavirus enhancer. Kamachi Y; Ogawa E; Asano M; Ishida S; Murakami Y; Satake M; Ito Y; Shigesada K J Virol; 1990 Oct; 64(10):4808-19. PubMed ID: 2168969 [TBL] [Abstract][Full Text] [Related]
22. Transforming but not immortalizing oncogenes activate the transcription factor PEA1. Wasylyk C; Imler JL; Wasylyk B EMBO J; 1988 Aug; 7(8):2475-83. PubMed ID: 3142763 [TBL] [Abstract][Full Text] [Related]
23. BOX DNA: a novel regulatory element related to embryonal carcinoma cell differentiation. Kihara-Negishi F; Tsujita R; Negishi Y; Ariga H Mol Cell Biol; 1993 Dec; 13(12):7747-56. PubMed ID: 7902532 [TBL] [Abstract][Full Text] [Related]
24. Essential AP-1 and PEA3 binding elements in the human urokinase enhancer display cell type-specific activity. Nerlov C; Rørth P; Blasi F; Johnsen M Oncogene; 1991 Sep; 6(9):1583-92. PubMed ID: 1923525 [TBL] [Abstract][Full Text] [Related]
26. Two blocks in Moloney murine leukemia virus expression in undifferentiated F9 embryonal carcinoma cells as determined by transient expression assays. Feuer G; Taketo M; Hanecak RC; Fan H J Virol; 1989 May; 63(5):2317-24. PubMed ID: 2704078 [TBL] [Abstract][Full Text] [Related]
27. Negative regulation of early polyomavirus expression in mouse embryonal carcinoma cells. Cremisi C; Babinet C J Virol; 1986 Sep; 59(3):761-3. PubMed ID: 3016339 [TBL] [Abstract][Full Text] [Related]
28. Two different factors bind to the alpha-domain of the polyoma virus enhancer, one of which also interacts with the SV40 and c-fos enhancers. Piette J; Yaniv M EMBO J; 1987 May; 6(5):1331-7. PubMed ID: 3038517 [TBL] [Abstract][Full Text] [Related]
29. Negative and positive factors determine the activity of the polyoma virus enhancer alpha domain in undifferentiated and differentiated cell types. Wasylyk B; Imler JL; Chatton B; Schatz C; Wasylyk C Proc Natl Acad Sci U S A; 1988 Nov; 85(21):7952-6. PubMed ID: 2847148 [TBL] [Abstract][Full Text] [Related]
30. Isolation and characterization of polyoma virus mutants able to develop in embryonal carcinoma cells. Vasseur M; Kress C; Montreau N; Blangy D Proc Natl Acad Sci U S A; 1980 Feb; 77(2):1068-72. PubMed ID: 6244578 [TBL] [Abstract][Full Text] [Related]
31. Identification of proteins binding to the F441 locus of polyomavirus B enhancer that are required for its activity in embryonic carcinoma cells. DasGupta S; Shivakumar CV; Das GC J Gen Virol; 1993 Apr; 74 ( Pt 4)():597-605. PubMed ID: 8385690 [TBL] [Abstract][Full Text] [Related]
32. Unique requirement for the PyF441 mutation for polyomavirus infection of F9 embryonal carcinoma cells. Tseng RW; Williams T; Fujimura FK J Virol; 1988 Aug; 62(8):2896-902. PubMed ID: 2839708 [TBL] [Abstract][Full Text] [Related]
33. PEA3 is a nuclear target for transcription activation by non-nuclear oncogenes. Wasylyk C; Flores P; Gutman A; Wasylyk B EMBO J; 1989 Nov; 8(11):3371-8. PubMed ID: 2555163 [TBL] [Abstract][Full Text] [Related]
34. The capacity of polyomavirus enhancer binding protein 2alphaB (AML1/Cbfa2) to stimulate polyomavirus DNA replication is related to its affinity for the nuclear matrix. Chen LF; Ito K; Murakami Y; Ito Y Mol Cell Biol; 1998 Jul; 18(7):4165-76. PubMed ID: 9632801 [TBL] [Abstract][Full Text] [Related]
35. Biological activities of oligonucleotides spanning the F9 point mutation within the enhancer region of polyomavirus DNA. Satake M; Furukawa K; Ito Y J Virol; 1988 Mar; 62(3):970-7. PubMed ID: 2828692 [TBL] [Abstract][Full Text] [Related]
36. A mutated polyoma virus enhancer which is active in undifferentiated embryonal carcinoma cells is not repressed by adenovirus-2 E1A products. Hen R; Borrelli E; Fromental C; Sassone-Corsi P; Chambon P Nature; 1986 May 15-21; 321(6067):249-51. PubMed ID: 3012353 [TBL] [Abstract][Full Text] [Related]
37. Site-directed mutagenesis of hepatocyte nuclear factor (HNF) binding sites in the mouse transthyretin (TTR) promoter reveal synergistic interactions with its enhancer region. Costa RH; Grayson DR Nucleic Acids Res; 1991 Aug; 19(15):4139-45. PubMed ID: 1870969 [TBL] [Abstract][Full Text] [Related]
38. Synergistic interactions between overlapping binding sites for the serum response factor and ELK-1 proteins mediate both basal enhancement and phorbol ester responsiveness of primate cytomegalovirus major immediate-early promoters in monocyte and T-lymphocyte cell types. Chan YJ; Chiou CJ; Huang Q; Hayward GS J Virol; 1996 Dec; 70(12):8590-605. PubMed ID: 8970984 [TBL] [Abstract][Full Text] [Related]
39. The nuclear protooncogenes c-jun and c-fos as regulators of DNA replication. Murakami Y; Satake M; Yamaguchi-Iwai Y; Sakai M; Muramatsu M; Ito Y Proc Natl Acad Sci U S A; 1991 May; 88(9):3947-51. PubMed ID: 1850842 [TBL] [Abstract][Full Text] [Related]
40. Transactivation of the Moloney murine leukemia virus and T-cell receptor beta-chain enhancers by cbf and ets requires intact binding sites for both proteins. Sun W; Graves BJ; Speck NA J Virol; 1995 Aug; 69(8):4941-9. PubMed ID: 7609063 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]